Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Galvin

Behavioral Neurology & Neuropsychiatry Boca Raton, FL Medical Doctor

NPI 1760408074 CMS profile 215215

7700 Camino Real Ste 200, Boca Raton, FL 33433

Open in the dashboard

General payments

$316,651

153 records reported · program years 2019–2025

Research payments

$44,611

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$369,262 paid to institutions, not to them · program years 2019–2024

Through program year 2025, James Galvin of Boca Raton, FL is reported in the CMS Open Payments database as having received $316,651 across 153 general payments and $44,611 in research payments paid to them. Separately, studies naming them as principal investigator received $369,262 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Behavioral Neurology & Neuropsychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,324 32
2024 General $53,018 39
2023 General $30,697 25
2022 General $84,249 32
2021 General $72,183 15
2021 Research $10,611 2
2020 General $15,179 8
2019 General $18,000 2
2019 Research $34,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Galvin
  • Behavioral Neurology & Neuropsychiatry median
  • Middle half of Behavioral Neurology & Neuropsychiatry
  • National median

In program year 2025, general payments to James Galvin were reported at $43,324. Among 74 Behavioral Neurology & Neuropsychiatry profiles paid that year, the median was $152 and the middle half received between $53 and $1,035.

Show as a table
Year James Galvin Behavioral Neurology & Neuropsychiatry median Middle half National median
2019 $18,000 $211 $86–$990 $163
2020 $15,179 $270 $54–$1,600 $114
2021 $72,183 $267 $60–$1,036 $132
2022 $84,249 $255 $69–$1,314 $149
2023 $30,697 $170 $50–$1,103 $160
2024 $53,018 $173 $39–$1,488 $164
2025 $43,324 $152 $53–$1,035 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $150,650 57 payments
  2. Eisai Inc. $82,412 31 payments
  3. Lilly USA, LLC $25,585 16 payments
  4. Eli Lilly and Company $14,322 7 payments
  5. Beckman Coulter, Inc. $13,117 10 payments
  6. Roche Molecular Systems, Inc. $10,004 2 payments
  7. Otsuka America Pharmaceutical, Inc. $8,717 6 payments
  8. E.R. Squibb & Sons, L.L.C. $5,411 7 payments
  9. Ge Healthcare $4,939 10 payments
  10. Roche Diagnostics International Ltd $1,180 1 payment
  11. Other $317 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $279,622 66 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,980 5 payments
  3. Travel and Lodging $12,542 31 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $6,760 1 payment
  5. Food and Beverage $2,747 50 payments
Products named General payments · program years 2019–2025
  1. ADUHELM $57,333 23 payments
  2. Leqembi $15,619 17 payments
  3. REXULTI $8,717 6 payments
  4. KISUNLA $7,082 12 payments
  5. DXI 9000 Access Immunoassay Analyzer $4,680 1 payment
  6. DaTscan $4,400 2 payments
  7. ACCESS 2 $675 4 payments
  8. Dayvigo $540 1 payment
  9. SPINRAZA $394 5 payments
  10. ADLARITY $138 1 payment
  11. Other $97 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biogen, Inc. $44,611 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

29

Median for Neurology: 833

Drug cost

$407

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Donepezil Hcl Generic 29 $407

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$12,389

Medicare's payments for the services billed

Medicare patients

49

Average age 77

Services billed

97

23 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 69%
High blood pressure 61%
Arthritis 57%
Depression 45%
Ischemic heart disease 37%
Chronic kidney disease 29%
Osteoporosis 27%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $7,712
$7,712 — —
KISUNLA
  • Lilly USA, LLC $1,457
  • Eli Lilly and Company $625
$2,082 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Behavioral Neurology & Neuropsychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record